Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection

Pan,Zhangchi; Zhang,Lu; Liu,Chen; Huang,Xiaobing; Shen,Songfei; Lin,Xiaoyan; Shi,Chunmei

doi:10.3892/ol.2019.10459

Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection

Authors:
- Zhangchi Pan
- Lu Zhang
- Chen Liu
- Xiaobing Huang
- Songfei Shen
- Xiaoyan Lin
- Chunmei Shi
View Affiliations

Affiliations: Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Clinical Laboratories, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Oncology, Fujian Magaw Memorial Hospital, Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: June 7, 2019 https://doi.org/10.3892/ol.2019.10459
Pages: 1513-1520

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the significance of the neutrophil to lymphocyte ratio (NLR) in peripheral blood of patients with small cell lung cancer (SCLC) when selecting a first‑line treatment. A total of 73 patients with SCLC who had complete clinical data and sought treatment at Fujian Medical University Union Hospital between January 2014 and May 2016 were included. Data were retrospectively analyzed, utilizing a receiver operating characteristic curve to determine the NLR cut‑off value. Out of the 73 patients, 39 were classified as high‑NLR (NLR ≥3.80) and 34 as low‑NLR (NLR <3.80). Compared with the high‑NLR group, patients in the low‑NLR group had a longer progression free survival (PFS); however, there was no statistically significant difference in overall survival (OS) time. Patients with a high NLR had a significantly longer PFS (P=0.021) and OS time (P=0.042) when treated with a etoposide/cisplatin (EP) therapy regimen, compared with those treated with etoposide/carboplatin (EC). PFS was the longest in the high‑NLR patients with limited stage (LS; P=0.002). Among the patients receiving the EC regimen, the PFS of the low‑NLR group was significantly longer compared with the high‑NLR group (P=0.003). Patients in the low‑NLR group who received thoracic radiotherapy had a longer PFS (P=0.011), when comparing patients in the low‑NLR group who did not receive thoracic radiotherapy, and within this group the therapeutic effect of radiation was the greatest in LS patients. Compared with the high‑NLR group, the low‑NLR group patients who received cranial radiotherapy had a significantly longer PFS (P=0.039). For the initial evaluation of patients with SCLC, pre‑treatment NLR may be of significance for selecting first‑line chemotherapy agents. As the present study was retrospective and investigated a limited number of patients, further research and prospective studies are warranted.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Klutker G, Sauer R and Fietkau R: Combined treatment modality in small cell lung cancer: The impact of radiotherapy on survival. Strahlenther Onkol. 184:61–66. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kurup A and Hanna NH: Treatment of small cell lung cancer. Crit Rev Oncol Hematol. 52:117–126. 2004. View Article : Google Scholar : PubMed/NCBI
4	Puglisi M, Dolly S, Faria A, Myerson JS, Popat S and O'Brien ME: Treatment options for small cell lung cancer-do we have more choices? Br J Cancer. 102:629–638. 2010. View Article : Google Scholar : PubMed/NCBI
5	Gaspar LE, Mcnamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS and Bonner JA: Small-cell lung cancer: Prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 10:115–122. 2009.
6	Murray N and Turrisi AT III: A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 1:270–278. 2006. View Article : Google Scholar : PubMed/NCBI
7	Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol. 30:1692–1698. 2012. View Article : Google Scholar : PubMed/NCBI
8	O'Dwyer PJ and Calvert AH: Platinum analogs. Cancer: Principles and Practice of Oncology. DeVita VT, Lawrence TS and Rosenbery SA: 10th. Lippincott Williams & Wilkins; Philidelphia, PA: pp. 199–207. 2015
9	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999. View Article : Google Scholar : PubMed/NCBI
10	O'Callaghan DS, O'Donnell D, O'Connell F and O'Byrne KJ: The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 5:2024–2036. 2010. View Article : Google Scholar : PubMed/NCBI
11	Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T and Tachibana M: Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 79:1085–1091. 2012. View Article : Google Scholar : PubMed/NCBI
12	Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T and Maehara Y: Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: A retrospective analysis. Ann Surg. 258:301–305. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y and Hu BS: The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving Sorafenib. Asian Pac J Cancer Prev. 14:5527–5531. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yao Y, Yuan D, Liu H, Gu X and Song Y: Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 62:471–479. 2013. View Article : Google Scholar : PubMed/NCBI
15	Unal D, Eroglu C, Kurtul N, Oguz A and Tasdemir A: Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 14:5237–5242. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kacan T, Babacan NA, Seker M, Yucel B, Bahceci A, Eren AA, Eren MF and Kilickap S: Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev. 15:2089–2094. 2014. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
18	Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG and Buhl R: Staging small cell lung cancer: Veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease? Lung Cancer. 37:271–276. 2002. View Article : Google Scholar : PubMed/NCBI
19	Naidoo J, Kehoe M, Sasiadek W, Hacking D and Calvert P: Prophylactic cranial irradiation in small cell lung cancer: A single institution experience. Ir J Med Sci. 183:129–132. 2014. View Article : Google Scholar : PubMed/NCBI
20	Byers LA and Rudin CM: Small cell lung cancer: Where do we go from here? Cancer. 121:664–672. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ettinger DS and Aisner J: Changing face of small-cell lung cancer: Real and artifact. J Clin Oncol. 24:4526–4527. 2006. View Article : Google Scholar : PubMed/NCBI
22	van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011. View Article : Google Scholar : PubMed/NCBI
23	Evans W, Shepherd FA, Feld R, Osoba D, Dang P and Deboer G: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 3:1471–1477. 1885. View Article : Google Scholar
24	Hatfield LA, Huskamp HA and Lamont EB: Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients. J Oncol Pract. 12:666–673. 2016. View Article : Google Scholar : PubMed/NCBI
25	Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 5:601–607. 1994. View Article : Google Scholar : PubMed/NCBI
26	Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T and Saijo N: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 97:162–169. 2007. View Article : Google Scholar : PubMed/NCBI
27	Pillar J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH, Leenen LP, Pickkers P and Koenderman L: A subset of neutronphils in human systemic inflammation inhibits t cell responses through mac-1. J Clin Invest. 122:327–336. 2012. View Article : Google Scholar : PubMed/NCBI
28	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
29	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
30	Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P and Ferri L: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 123:3446–3458. 2013. View Article : Google Scholar
31	Demers M and Wagner DD: Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2:229462013. View Article : Google Scholar
32	Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
33	Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunology. 11:889–896. 2010. View Article : Google Scholar
34	Allavena P, Sica A, Garlanda C and Mantovani A: The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 222:155–161. 2008. View Article : Google Scholar : PubMed/NCBI
35	Deng M, Ma X, Liang X, Zhu C and Wang M: Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget. 8:37200–37207. 2017.PubMed/NCBI
36	Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces Y, Mansfield A, Molina J and Yang P: Nomograms predict overall survival for patients with small-cell lung Cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol. 10:1213–1220. 2015. View Article : Google Scholar : PubMed/NCBI
37	Hong X, Cui B, Wang M, Yang Z, Wang L and Xu Q: Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 236:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
38	Wang ZY, Zhang JA, Wu XJ, Liang YF, Lu YB, Gao YC, Dai YC, Yu SY, Jia Y, Fu XX, et al: IL-6 inhibition reduces STAT3 activation and enhances the antitumor effect of carboplatin. Mediators Inflamm. 2016:80264942016. View Article : Google Scholar : PubMed/NCBI
39	Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl J Med. 327:1618–1624. 1992. View Article : Google Scholar : PubMed/NCBI